We are advancing new strategies for ultra-low-cost monoclonal antibody (mAb) manufacturing. Our approach emphasizes process intensification through simplified, non-chromatographic downstream recovery. Continuous operations and automated control are being integrated to improve robustness and scalability. These innovations target the critical cost drivers in mAb production, enabling broader access to biologics globally.